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Development of placental vascular tree is structurally and func-
tionally required for both adequate placental growth and delivery
of nutrients from mother to the fetus. Impaired placental angio-
genesis has been implicated in the pathophysiology of pregnancy
complications which have immediate and long-lasting effects on
themother and her child; such complications include fetal growth
restriction and macrosomia as well as pre-eclampsia and gesta-
tional diabetes. The mechanisms underlying the deregulation of
placental angiogenesis include amisbalance between the secretion
and activity of pro-angiogenic vs. anti-angiogenic factors. Despite
this, therapies for improving placental angiogenesis in patholog-
ical pregnancies have not been directly tested in humans and the
aim of this Research Topic in Frontiers is to highlight potential
therapeutic targets.
Physical activity during pregnancy might be effective for
reducing the risk of developing pregnancy complications. In this
regard, Rodriguez and Gonzalez (2014) explain how physical
activity affects placental endothelial shear stress and vasodilation,
via synthesis and release of nitric oxide (NO). Whilst these pro-
cesses are relatively well-described in the adult circulation, they
are not completely understood in the feto-placental circulation.
Then, they analyze how training affects hemodynamics in the
mother, which may favor blood supply to the placenta, favoring
placental angiogenesis, glucose and oxygen delivery and thereby
fetal growth and development. Considering this concept, the
potential beneficial effects of moderate levels of maternal exercise
may constitute a non-pharmacological intervention for improv-
ing maternal and fetal hemodynamic alterations observed during
pathological pregnancies such as pre-eclampsia, gestational dia-
betes, or intrauterine growth restriction.
On the other hand, Herrera et al. (2014) characterizes
the response of the umbilical-placental vasculature to hypoxia
induced experimentally or through living at high-altitude. They
later describe how hypoxia and oxidative stress may impact pla-
cental establishment and therefore have consequences for embry-
onic development from the early stages of gestation. The authors
also highlight the implications of a prolonged hypoxic environ-
ment in inducing adaptive responses of the placenta in pregnan-
cies at high altitude, or conversely in the development of placental
vascular pathologies such as those observed during intrauterine
growth restriction and pre-eclampsia. The clinical significance of
these findings are discussed, emphasizing that balancing levels of
oxidative stress may be a target for improving placental vascular
alterations.
Impaired remodeling of maternal spiral arteries by invasive
placental trophoblast is thought to be the primary cause of
intrauterine hypoxia and the pathophysiology of pre-eclampsia
and/or intrauterine growth restriction. In this regard, Salomon
et al. (2014) presented novel data which improve our under-
standing in the interactions of trophoblast with vascular smooth
muscle cells (VSMC) via exosomes. They assess exosomes release
and content in two extravillous trophoblast cell lines (JEC-3 and
HTR-8/SVneo), and relate their observations with the capac-
ity of these exosomes for promoting migration of VSMC. They
found high release, differential composition, and high promotion
of VSMC migration in exosomes released from HTR-8/SVneo
cells compared with JEC-3 cells. Interestingly, their findings indi-
cate that modulation of VSMC migration depends on exosome
cargo, exosomal structural integrity, and intracellular incorpo-
ration of these exosomes into VSMC. These promising results
highlight the potential of exosomes as diagnostic biomarkers
of normal or abnormal placentation, or perhaps may consti-
tute an alternative method for introducing molecules with a
therapeutic aim.
Bidwell and George (2014), also show that employing a car-
rier protein called elastin-like polypeptide (ELP) may provide a
method for delivering therapeutic agents/drugs to the placenta
during pathological pregnancies, including pre-eclampsia. These
particular peptides may offer many advantages since researchers
could manipulate their length, sequence, and therefore biochemi-
cal properties in order to selectively target a particular cell and/or
tissue. More importantly, due to the high molecular weight of
ELP, it cannot cross the placenta avoiding fetal exposure and
potential developmental defects. Preclinical studies are currently
underway exploring whether fusing ELP with proteins like vas-
cular endothelial growth factor (ELP-VEGF), the p50 subunit of
NF-kB or with the Nox2 docking sequence (Nox2ds) affects their
half-life, or activity.
Cindrova-Davies (2014) provides an overview of the patho-
physiology of pre-eclampsia. In particular, the contribution of
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hypoxia, the equilibrium between oxidants-antioxidants, soluble
vascular endothelial growth factor receptor 1 (s-Flt1), the
bioavailability of NO and hydrogen sulfide (H2S) and the lev-
els of pro-inflammatory and endoplasmic reticulum (ER) stress
in the development of this disease are discussed. Considering
this biological background, She identifies potential pharmaco-
logical targets for improving placental function in pre-eclampsia.
These pharmacological tools may include ER chaperones such as
ursodeoxycholic acid, as well as vasoactive molecules including L-
arginine, NO-donors, H2S and statins; some of them are indeed
being tested in clinical trials.
Also on the topic of pre-eclampsia, Escudero et al. (2014)
propose a challenging hypothesis that the impaired adenosine-
mediated placental angiogenesis observed in pre-eclampsia might
also be present in the offspring at birth and lead to a reduction in
microvascular formation and compromised hemodynamic regu-
lation. According with this hypothesis, adenosine could constitute
another avenue for recovering both impaired placental angiogen-
esis and future complication in the offspring.
On the other hand, Guzman-Gutierrez et al. (2014) raise the
notion that the placenta controls the bioavailability of thyrox-
ine (T4) and tri-iodothyronine (T3) in the fetal circulation. They
propose that the placenta may respond in an adaptive fashion
to low maternal T4 although placental control of T3/T4 may be
impaired during chronic maternal hypothyroxemia or hypothy-
roidism. They also present evidence suggesting that T3/T4 con-
trols endothelial function, via effects on placental angiogenesis
and the synthesis and release of vasodilators and vasoconstric-
tors. Additionally, they suggest that low levels of T4 observed
during gestational diabetes might contribute to impaired vascular
function observed in this disease.
Nevertheless, Saez et al. (2014) review how ER stress could
impair endothelium migration, one of the initial steps in the
angiogenesis process. In addition they suggest that obesity, a well-
described condition associated with ER stress, could also drive
impaired placental angiogenesis. Their analysis includes charac-
terizing potential intracellular signaling pathways that could link
obesity mediated ER stress with alteration in the pro-migratory
signals. Then, as described also by Cindrova-Davies in this issue,
ER stress modulators might constitute a potential therapy for
improving placental angiogenesis.
For understanding regulators of angiogenesis process, Murthi
et al. (2014) describe how homeobox genes regulate the tran-
scription of genes essential for angiogenesis in the human
placenta. Their analysis includes a description of homeobox
genes differentially expressed in the macrovascular and microvas-
cular endothelium derived from the feto-placental vessels,
which may improve our understanding of physiological and
pathological placental angiogenesis. Therefore, manipulating
the expression of homeobox genes and/or their targets in the
placenta may serve as an alternate method to improve the
outcome of pregnancies compromised by perturbed placental
angiogenesis.
Another, cutting-edge analysis related with differential gene
expression in placental endothelium and the vascular tree is
reviewed by Casanello et al. (2014). The authors focus on how
epigenetic mechanisms play a role in endothelial physiology,
providing the example that the promoters of endothelial nitric
oxide synthase (eNOS), and arginase 2 (Arg-2) are differen-
tially methylated in the endothelium of arteries or veins, as well
as in macro or microcirculation in the human feto-placental
vasculature. Interestingly, by studying the patterns of DNA
methylation, they suggest an “arterization” of human chorionic
endothelium vein derived from pregnancies with intrauterine
growth restriction. They also suggest that changes in the activ-
ity and/or expression DNA-methytransferases might comprise
potential new targets for both understanding the control of gene
expression in the fetal-placental unit, as well as for identifying
new potential targets for therapy.
As presented in this Research Topic, the study of placental
angiogenesis constitutes a niche of research not only for under-
standing pathophysiology of human pregnancy diseases such as
pre-eclampsia, intrauterine growth restriction, or gestational dia-
betes; but also for the development of therapeutic tools which
promote placental vascularization and function and thus improve
fetal development with lasting effects into adult life. As described
in each paper in this Research Topic so much is unknown in
this field, therefore I would like to encourage researchers to con-
tinue contributing to our understanding of placental angiogenesis
during normal and pathological conditions. Finally, but more
importantly, I would like to thank all authors who have con-
tributed papers, as well as, the reviewers and editorial board for
helping us in underscore the importance of this Research Topic.
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